AI news ·
SkinVision launches SkinVision Pro globally at HLTH Europe
SkinVision Pro sends AI skin cancer risk signals to clinics before consultations. In Dutch tests, 80% of low-risk patients skipped a doctor visit; 24% of high-risk ones had cancer.
SkinVision launched SkinVision Pro globally at HLTH Europe on June 16, 2026, a platform that connects its AI-powered skin health assessment directly to medical practices, supplying clinicians with structured patient data before a consultation ever begins. The launch responds to a tripling of skin cancer incidence over the past two decades, dermatology wait times stretching to six months in some health systems, and a fragmented system where patients, GPs and specialists rarely share a consistent view of skin health history.
Closing the information gap before the appointment
Patients use the SkinVision Service at home to photograph a concerning skin spot. The AI returns a risk indication and either recommends monitoring or advises a doctor visit. The medical practice, meanwhile, sees the lesion image, reported symptoms and risk level through a dedicated dashboard, integrated into existing healthcare systems. SkinVision handles all patient queries about the service directly, so practices receive results without added administrative work.
The platform exemplifies how AI for Healthcare tools are being embedded directly into clinical workflows, giving practitioners structured assessments that arrive ahead of the scheduled visit. This means consultations start with both sides prepared, rather than beginning from a blank slate.
Clinical validation and early real-world results
The SkinVision Service holds a CE mark as a Class IIa medical device, with sensitivity above 90% and specificity of 89% for skin cancer detection. Early data from Dutch primary care users in the first quarter of 2026 showed 80% of patients receiving a low-risk indication were reassured at home and did not schedule a doctor visit. Among those flagged as high-risk, 24% reported a confirmed skin cancer diagnosis. These figures are based on self-reported feedback, but they align with the device's clinical validation and suggest a meaningful impact in primary care settings.
"Skin conditions account for around 15% of GP consultations. SkinVision Pro connects healthcare professionals to their patients' SkinVision medical device results, directly within their existing workflow, helping results reach the doctor sooner and making the primary care pathway more efficient," said Erik de Heus, CEO of SkinVision.
What the early adopter package includes
Medical practices joining now get dashboard access, SkinVision Academy training, a physical and digital Welcome Pack, waiting room materials like flyers and videos to help onboard patients, structured assessment reports, and a dedicated customer support channel. The offer is available at skinvision.com/pro.
SkinVision, founded in 2012 and headquartered in Amsterdam, has supported more than 6 million skin checks across 3 million users worldwide. The service does not diagnose skin cancer and does not replace a doctor or dermatologist.
Why this matters for healthcare professionals
SkinVision Pro shifts part of the diagnostic triage to the patient's home, with a clinically validated risk filter that can reduce unnecessary GP visits and shorten the path to specialist care for high-risk lesions. For practices, the platform delivers actionable, structured information within existing systems, cutting down the time spent gathering background during the consultation. In a climate of growing skin cancer rates and strained appointment slots, having a vetted risk signal rather than an unstructured patient concern changes how clinicians can allocate their attention.